Crinetics Pharmaceuticals (CRNX) Receivables (2024 - 2026)

Crinetics Pharmaceuticals' Receivables history runs 6 years deep, the most recent figure standing at $14.6 million for Q1 2026.

• In Q1 2026, Receivables changed N/A year-over-year to $14.6 million; the TTM figure through Mar 2026 stood at $14.6 million (changed N/A YoY), while the FY2025 annual figure was $8.4 million, changed 0.48% from the prior year.
• Receivables for Q1 2026 stood at $14.6 million, up from $8.4 million in the prior quarter.
• The five-year high for Receivables was $14.6 million in Q1 2026, with the low at $8.3 million in Q4 2024.
• The 3-year median for Receivables is $8.4 million (2025), against an average of $10.4 million.
• Peak annual rise in Receivables reached 0.48% in 2025, while the deepest fall reached 0.48% in 2025.
• Crinetics Pharmaceuticals' Receivables stood at $8.3 million in 2024, then grew by 0.48% to $8.4 million in 2025, then soared by 75.33% to $14.6 million in 2026.
• Business Quant data shows CRNX's Receivables at $14.6 million in Q1 2026, $8.4 million in Q4 2025, and $8.3 million in Q4 2024.